These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1181 related items for PubMed ID: 33197395

  • 1. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Göhring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM-AHF investigators.
    Lancet; 2020 Dec 12; 396(10266):1895-1904. PubMed ID: 33197395
    [Abstract] [Full Text] [Related]

  • 2. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Ponikowski P, Kirwan BA, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Khintibidze I, Kragten H, Martinez FA, McDonagh T, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Jankowska EA.
    Eur J Heart Fail; 2019 Dec 12; 21(12):1651-1658. PubMed ID: 31883356
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
    Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I, IRONMAN Study Group.
    Lancet; 2022 Dec 17; 400(10369):2199-2209. PubMed ID: 36347265
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial.
    Vanobberghen F, Lweno O, Kuemmerle A, Mwebi KD, Asilia P, Issa A, Simon B, Mswata S, Schmidlin S, Glass TR, Abdulla S, Daubenberger C, Tanner M, Meyer-Monard S.
    Lancet Glob Health; 2021 Feb 17; 9(2):e189-e198. PubMed ID: 33245866
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
    Khalafallah AA, Yan C, Al-Badri R, Robinson E, Kirkby BE, Ingram E, Gray Z, Khelgi V, Robertson IK, Kirkby BP.
    Lancet Haematol; 2016 Sep 17; 3(9):e415-25. PubMed ID: 27570088
    [Abstract] [Full Text] [Related]

  • 9. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
    Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF, HEART-FID Trial Investigators.
    Circ Heart Fail; 2021 May 17; 14(5):e008100. PubMed ID: 34003690
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.
    Martens P, Dupont M, Dauw J, Somers F, Herbots L, Timmermans P, Verwerft J, Mullens W.
    ESC Heart Fail; 2019 Dec 17; 6(6):1208-1215. PubMed ID: 31562751
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
    Yeo TJ, Yeo PSD, Hadi FA, Cushway T, Lee KY, Yin FF, Ching A, Li R, Loh SY, Lim SL, Wong RC, Tai BC, Richards AM, Lam CSP.
    ESC Heart Fail; 2018 Apr 17; 5(2):344-353. PubMed ID: 29345426
    [Abstract] [Full Text] [Related]

  • 15. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
    Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, CONFIRM-HF Investigators.
    Eur Heart J; 2015 Mar 14; 36(11):657-68. PubMed ID: 25176939
    [Abstract] [Full Text] [Related]

  • 16. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA, Keating GM.
    Drugs; 2009 Mar 14; 69(6):739-56. PubMed ID: 19405553
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P, Banké-Bochita J.
    Arzneimittelforschung; 2010 Mar 14; 60(6a):362-72. PubMed ID: 20648928
    [Abstract] [Full Text] [Related]

  • 18. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial.
    Spahn DR, Schoenrath F, Spahn GH, Seifert B, Stein P, Theusinger OM, Kaserer A, Hegemann I, Hofmann A, Maisano F, Falk V.
    Lancet; 2019 Jun 01; 393(10187):2201-2212. PubMed ID: 31036337
    [Abstract] [Full Text] [Related]

  • 19. Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.
    von Haehling S, Doehner W, Evertz R, Garfias-Veitl T, Derad C, Diek M, Karakas M, Birkemeyer R, Fillippatos G, Lainscak M, Butler J, Ponikowski P, Böhm M, Friede T, Anker SD.
    Eur Heart J; 2024 Oct 05; 45(37):3789-3800. PubMed ID: 39185895
    [Abstract] [Full Text] [Related]

  • 20. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
    Kim YW, Bae JM, Park YK, Yang HK, Yu W, Yook JH, Noh SH, Han M, Ryu KW, Sohn TS, Lee HJ, Kwon OK, Ryu SY, Lee JH, Kim S, Yoon HM, Eom BW, Choi MG, Kim BS, Jeong O, Suh YS, Yoo MW, Lee IS, Jung MR, An JY, Kim HI, Kim Y, Yang H, Nam BH, FAIRY Study Group.
    JAMA; 2017 May 23; 317(20):2097-2104. PubMed ID: 28535237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.